Effectiveness of natriuretic peptide-guided treatment of chronic heart failure. A meta-analysis

被引:2
|
作者
Gamino-Arroyo, Ana-Estela [1 ]
Prado-Galbarro, Francisco-Javier [2 ,3 ,4 ]
Garcia-Perez, Sonia [4 ,5 ]
Sanchez-Piedra, Carlos [4 ]
机构
[1] Hosp Infantil Mexico Dr Federico Gomez, Unidad Infectol, Ciudad De Mexico, Mexico
[2] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Ciudad De Mexico, Mexico
[3] Inst Nacl Salud Publ, Unidad Salud Reprod, Cuernavaca, Morelos, Mexico
[4] Inst Salud Carlos III, Agencia Evaluac Tecnol Sanitarias, Madrid, Spain
[5] REDISSEC, Unidad Invest, Madrid, Spain
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2018年 / 88卷 / 03期
关键词
Heart failure; Natriuretic peptide; Meta-analysis; Therapy; NT-proBNP; Mexico;
D O I
10.1016/j.acmx.2017.02.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the efficacy of natriuretic peptide (NP)-guided therapy compared to clinically-guided therapy in reducing mortality and hospital admissions in chronic heart failure (HF) patients. Methods: Randomised clinical trials (RCT) were selected through a systematic review. Four meta-analyses were conducted for the outcomes of overall mortality, HF-related mortality, overall hospital admissions, and HF-related hospital admissions. Heterogeneity between studies and publication bias were also assessed. Results: Nine RCTs were found with a total of 1914 patients. NP-guided therapy significantly reduced overall mortality and HF-related hospital admissions. No significant results were found for HF-related mortality and overall hospital admissions. Some clinical heterogeneity regarding interventions performed was found between studies. Publication bias was found for HF-related and overall hospital admissions. Conclusions: NP-guided therapy seems to improve outcomes compared to clinically-guided therapy. However, heterogeneity found between interventions might reduce the generalisation of these results. Specific interventions of the clinical trials should be examined when making recommendations regarding NP-guided therapy. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [31] Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis
    Khan, Muhammad Shahzeb
    Siddiqi, Tariq Jamal
    Usman, Muhammad Shariq
    Sreenivasan, Jayakumar
    Fugar, Setri
    Riaz, Haris
    Murad, M. H.
    Mookadam, Farouk
    Figueredo, Vincent M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 263 : 80 - 87
  • [32] The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran
    Rezapour, Aziz
    Palmer, Andrew J.
    Alipour, Vahid
    Hajahmadi, Marjan
    Jafari, Abdosaleh
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [33] B-type natriuretic peptide or amino-terminal pro-B-type natriuretic peptide-guided treatment of heart failure: what is the next STEP?
    Troughton, Richard W.
    Nicholls, M. Gary
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (10) : 1046 - 1048
  • [34] Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome
    Karlstrom, Patric
    Alehagen, Urban
    Boman, Kurt
    Dahlstrom, Ulf
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (10) : 1096 - 1103
  • [35] Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials
    Adamson, Philip B.
    Ginn, Greg
    Anker, Stefan D.
    Bourge, Robert C.
    Abraham, William T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (03) : 426 - 433
  • [36] Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy
    Diez, Javier
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (02) : 167 - 176
  • [37] Natriuretic Peptide Guided Heart Failure Management
    Mohammed, Asim A.
    Januzzi, James L., Jr.
    CURRENT CLINICAL PHARMACOLOGY, 2009, 4 (02): : 87 - 94
  • [38] Probrain Natriuretic Peptide for assessment of efficacy in heart failure treatment
    Adem Ozkara
    Faruk Turgut
    Yusuf Selcoki
    Aydin Karanfil
    Melike Rusen Metin
    Mehmet Kanbay
    Oguz Tekin
    Ali Akcay
    Advances in Therapy, 2007, 24 : 1233 - 1239
  • [39] Probrain natriuretic peptide for assessment of efficacy in heart failure treatment
    Ozkara, Adem
    Turgut, Faruk
    Selcoki, Yusuf
    Karanfil, Aydin
    Metin, Mellike Rusen
    Kanbay, Mehmet
    Tekin, Oguz
    Akcay, Ali
    ADVANCES IN THERAPY, 2007, 24 (06) : 1233 - 1239
  • [40] Brain Natriuretic Peptide Chronic Heart Failure and More?
    Fitterman, Nick
    Amin, Alpesh
    HOSPITAL MEDICINE CLINICS, 2012, 1 (03) : E289 - E299